Reducing risk of adverse cardiovascular and renal outcomes for patients with atrial fibrillation and type 2 diabetes

Eur J Heart Fail. 2020 Jan;22(1):136-138. doi: 10.1002/ejhf.1685. Epub 2019 Dec 9.

Authors

Stephanie L Harrison¹, Deirdre A Lane^{1

2}, Gregory Y H Lip^{1

2}

Affiliations

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.
² Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

PMID: 31820530
DOI: 10.1002/ejhf.1685

No abstract available

Publication types

Editorial
Comment

MeSH terms

Atrial Fibrillation*
Benzhydryl Compounds
Diabetes Mellitus, Type 2*
Glucosides
Heart Failure*
Humans

Substances

Benzhydryl Compounds
Glucosides
empagliflozin